What are the typical symptoms and recommended management strategies for Sjögren's syndrome?

Sjögren's Syndrome: Symptoms and Management

Clinical Presentation

Sjögren's syndrome presents with a characteristic triad of sicca symptoms (dryness), fatigue, and musculoskeletal pain, affecting over 95% of patients, with potential systemic organ involvement and a 2-5% risk of lymphoma development. 1

Core Symptoms

• Sicca syndrome (dryness): Primarily affects eyes and mouth due to immune-mediated destruction of lacrimal and salivary glands, but can involve other mucosal surfaces 1, 2
• Fatigue: A central symptom significantly impacting quality of life 1
• Musculoskeletal pain: Commonly accompanies the disease 1

Systemic Manifestations

• Articular involvement: Joint symptoms are common 3
• Pulmonary disease: Can occur as part of systemic involvement 3
• Peripheral nervous system: Includes mononeuropathies, polyneuropathies, and autonomic neuropathies 4
• Cutaneous, renal, muscular, and neurological domains: May be affected with varying severity 1
• B-cell lymphoma: Develops in 2-5% of patients, predominantly marginal zone lymphomas, with standardized incidence ratios of 7-9 in population-based studies 1

Diagnostic Features

• Autoantibodies: Anti-Ro/SS-A (most specific), anti-La/SSB, antinuclear antibodies (most frequent) 1, 2
• Histopathology: Focal lymphocytic infiltration of exocrine glands on minor labial salivary gland biopsy 1, 2
• Prognostic markers: Cryoglobulins and hypocomplementemia 1

---

Management Approach

Management should follow a stepwise algorithm: first-line topical therapies for sicca symptoms, followed by systemic therapies tailored to organ-specific severity using ESSDAI scoring, with sequential escalation from glucocorticoids to immunosuppressants to biologics for refractory systemic disease. 1

Multidisciplinary Care Structure

• Coordination: Specialists in autoimmune diseases should coordinate diagnostic and therapeutic processes through shared decision-making with patients 1
• Team involvement: Rheumatology, internal medicine, oral health, ophthalmology, gynecology, dermatology, neurology, and primary care physicians 1, 5

---

Treatment Algorithm

Step 1: Sicca Symptoms (First-Line)

Topical therapies are the mandatory first approach for dryness, as no systemic intervention has been shown to reverse glandular dysfunction. 1

Ocular Dryness

• Artificial tear drops: Initial therapy 1
• Topical NSAIDs: For additional symptom control 1
• Topical corticosteroids: For inflammatory component 1
• Topical cyclosporine A: For refractory cases 1
• Serum tear drops: For severe, refractory ocular dryness 1

Oral Dryness

• Saliva substitutes: First-line topical therapy 1
• Oral muscarinic agonists (pilocarpine, cevimeline): To stimulate residual gland function 1

Step 2: Systemic Disease Management

Treatment intensity must be tailored to organ-specific severity using ESSDAI definitions: low activity (ESSDAI 1-4), moderate (5-13), or high (≥14). 1

Mild Systemic Disease

• Hydroxychloroquine: Consider for mild systemic manifestations 1, 5

Moderate to Severe Systemic Disease

Sequential or combined therapy following this hierarchy: 1

1. Glucocorticoids: Use at minimum effective dose and shortest duration necessary to control active disease 1

2. Immunosuppressive agents: Deploy primarily as glucocorticoid-sparing agents 1

   • Options include: cyclophosphamide, azathioprine, methotrexate, leflunomide, mycophenolate 1
   • No evidence supports choosing one agent over another 1

3. B-cell targeted therapies: Reserved for severe, refractory systemic disease 1

   • Rituximab: Primary biologic option 1, 5
   • Abatacept and belimumab: Alternative biologics 1

Step 3: Lymphoma Management

B-cell lymphoma treatment must be individualized according to WHO 2016 histological subtype and disease stage, managed by hematology/oncology. 1

Low-Grade Lymphomas

• Watchful waiting: May be appropriate when lymphoma only affects exocrine glands without constitutional symptoms or systemic features 1
• Rituximab plus bendamustine (BR): Recommended first-line for marginal zone lymphoma, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma in stage IV disease 1
• Radiotherapy: Consider for stage I or non-bulky stage II disease 1

Moderate/High-Grade Lymphomas

• Rituximab-based chemotherapy regimens: Standard approach 1

---

Critical Pitfalls to Avoid

• Do not attempt to "cure" sicca symptoms with systemic therapy: Glandular dysfunction remains stable for up to 12 years, and no intervention reverses it 1
• Do not overlook lymphoma surveillance: Maintain vigilance for constitutional symptoms, systemic features, and B-cell activation biomarkers 1
• Do not use glucocorticoids long-term: Minimize dose and duration to prevent cumulative toxicity 1
• Do not delay multidisciplinary evaluation: Systemic complications require timely identification and organ-specific management 3, 5
• Do not ignore peripheral neuropathy: Requires specific neurological evaluation and management protocols 4

---

Disease Activity Monitoring

• ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index): Use to classify systemic activity and guide treatment escalation 1
• ESSPRI (EULAR Sjögren's Syndrome Patient Reported Index): Monitor patient-reported outcomes including dryness, fatigue, and pain 5
• Treatment response: Defined as decrease of ≥3 points in global ESSDAI score 1